~~<i id='080D7868AB'><strike id='080D7868AB'><tt id='080D7868AB'><pre id='080D7868AB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：explore 2025-09-29 01:38:49 - browse：278

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Vertex non

Wikipedia

hotspot

focus

hotspot

Sen.BernieSanderstoldreportersthatMerck'sCEOrefusedtotestifyoveralackofexpertiseindrugpricing.Mariam

WSS

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Will Ozempic

Eli Lilly expects to double planned employment in Boston center

Biogen walks away from Aduhelm, years after polarizing approval

Syphilis numbers in the United States reach record heights

Merck CEO won’t testify in Senate, citing no expertise in drug prices

hotspot

fashion

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Senate committee scrutinizes Medicare Advantage brokers

Heart attack and stroke risk calculators need revising

CEOs share strategies for surviving biotech slump

Guidelines to prevent youth baseball injuries need more muscle

Humana’s losses in Medicare Advantage tank its stock

As demand for Covid shots wanes, Moderna seeks its next success

Why you shouldn’t ask, “What country has the best health care?”

Hepatitis C has a cure — but many Americans still lack access to it

Impact of Dobbs ruling felt at reproductive medicine meeting

hotspot

Merck, Johnson & Johnson CEOs will testify on high drug prices

FDA struggles to regulate food additives, sometimes for decades

Studies point to risks of excluding people with obesity from drug trials

Eli Lilly expects to double planned employment in Boston center

Investment in vaccine development is lagging, report finds

UnitedHealth’s board chair also owns a personal investment firm

hotspot

focus

hotspot

hotspot